Focused on developing innovative drugs that materially benefit patients with liver and gastrointestinal diseases

Non-alcoholic steatohepatitis (NASH) is one of the most common liver diseases

Irritable bowel syndrome with diarrhea affects ˜9 million people in the US

Inflammatory bowel disease is increasing in prevalence worldwide

Our Company

We are an experienced team with internal drug discovery and development expertise focused on building a pipeline of best-in-class oral drugs for liver and gastrointestinal diseases.

MET409 is an optimized next generation FXR agonist with a potential role in the treatment of non-alcoholic steatohepatitis (NASH), irritable bowel syndrome with diarrhea and inflammatory bowel diseases. Beyond our FXR program, we are focused on building a pipeline of novel drug candidates.

Focused on developing innovative drugs that materially benefit patients with liver and gastrointestinal diseases

Non-alcoholic steatohepatitis (NASH) is one of the most common liver diseases

Irritable bowel syndrome with diarrhea affects ˜9 million people in the US

Inflammatory bowel disease is increasing in prevalence worldwide

Our Company

Latest News

Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors

Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist

Programs